Deutsche Bank AG Buys 23,327 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Deutsche Bank AG increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 6.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 402,874 shares of the company’s stock after purchasing an additional 23,327 shares during the quarter. Deutsche Bank AG’s holdings in Viridian Therapeutics were worth $7,723,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of Viridian Therapeutics by 113.1% during the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after buying an additional 66,550 shares during the period. SG Americas Securities LLC increased its position in Viridian Therapeutics by 89.1% during the fourth quarter. SG Americas Securities LLC now owns 31,085 shares of the company’s stock valued at $596,000 after acquiring an additional 14,644 shares during the last quarter. Moody Aldrich Partners LLC bought a new position in Viridian Therapeutics in the fourth quarter valued at about $1,125,000. R Squared Ltd purchased a new position in Viridian Therapeutics in the fourth quarter worth about $26,000. Finally, Rhumbline Advisers boosted its position in Viridian Therapeutics by 13.1% in the fourth quarter. Rhumbline Advisers now owns 99,938 shares of the company’s stock worth $1,916,000 after purchasing an additional 11,594 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently commented on VRDN. Needham & Company LLC reduced their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada cut their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. JMP Securities decreased their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $36.70.

Viridian Therapeutics Stock Up 2.5%

NASDAQ VRDN opened at $12.94 on Friday. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.06 billion, a PE ratio of -3.00 and a beta of 0.57. The stock’s 50 day moving average is $13.41 and its 200 day moving average is $17.13.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.16 million. The business’s quarterly revenue was up .0% compared to the same quarter last year. Research analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.